CN106317059B - A kind of 2 (CB2) agonist of Cannabined receptor - Google Patents
A kind of 2 (CB2) agonist of Cannabined receptor Download PDFInfo
- Publication number
- CN106317059B CN106317059B CN201610689120.6A CN201610689120A CN106317059B CN 106317059 B CN106317059 B CN 106317059B CN 201610689120 A CN201610689120 A CN 201610689120A CN 106317059 B CN106317059 B CN 106317059B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- disease
- phenyl
- officinal salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WDJULWAELCTZFS-UHFFFAOYSA-N N#CN(CC1)CCC1c(cccc1)c1OC(F)(F)F Chemical compound N#CN(CC1)CCC1c(cccc1)c1OC(F)(F)F WDJULWAELCTZFS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The Pai Ding oxadiazoles and imidazo [1,2 a] pyrazines derivatives and/or their officinal salt and preparation method thereof being coupled the present invention relates to propionamide shown in a kind of formula I, and the pharmaceutical composition containing the compound.I compound represented of formula is a kind of 2 (CB2) agonist of potential Cannabined receptor, can be used for treatment and/or prevention of inflammation, inflammatory bowel disease, glaucoma, diabetes, kidney fibrosis, myocardial ischemia, myocardial infarction etc..Wherein, to substituent R1And R2Restriction referring to claims.
Description
Technical field
The invention belongs to medicinal chemistry arts, and in particular to the piperidines being coupled to a kind of propionamide described in claim
Oxadiazole and imidazo [1,2-a] pyrazine compounds and its physiologically acceptable salt, their preparation method and it
To prevent and/or treat pain, inflammation, inflammatory bowel disease, glaucoma, diabetes, diabetic retinopathy, artery athero-
It is hardening, age-related macular degeneration, acute hepatic failure, liver fibrosis, pulmonary fibrosis, kidney fibrosis, systemic fibrosing, scarce
Blood-reperfusion injury, acute allograft rejection, chronic allograft nephrosis, diabetic nephropathy, glomerulonephritis
Disease, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal damage, burn, hypertrophic scar, oulitis hair
Use in Cannabined receptors 2 (CB2) the agonist relevant disease such as hot, hepatic sclerosis or tumour, osteoporosis, neurodegeneration, palsy
On the way.
Technical background
Cannboid (cannabinoid, CB) is that therapeutic effect and mentalistic chemical substance are played in hemp, 1964,
Gaoni etc. to the main active tetrahydro-cannabinolic acid of cannabis plant, has carried out the confirmation of separation and stereochemical structure for the first time
(Gaoni,Y.et.al,J.Am.Chem.Soc,1964,86,1646).Subsequent researchers are divided into a series of from being obtained with synthesis
Cannabinoids compound (Felder, C.C.et.al, Mol.Interv, 2006,6,149).Traditional Cannabinoids chemical combination owner
To include five classes：1, using tetrahydro-cannabinolic acid as the classical Cannabinoids compound of representative, such compound is from natural plants
Cannabinoid of extraction and the like, tricyclic parent nucleus are its structural features；2, using AEA and 2-AG as in representative
Source property cannboid；3, using CP55940 as the non-classical Cannabinoids compound of representative, such compound is opening for classical cannboid
Ring derivatives；4, using WIN55212-2 as the amino alkyl indole class compound of representative；5, using SR141716A as the diaryl of representative
Pyrazole compound (Howlett, A.C.et.al, Pharmacol.Rev, 2002,54,161).
Meanwhile people also conduct extensive research the mechanism of action of Cannabinoids compound.Cannabinoid is made
For Cannabined receptor (cannabinoid receptor, CB-R) to realize its physiological activity, research at present has shown that, cannboid
Receptor includes two hypotypes：Cannabined receptor 1 (cannabinoid receptor 1, CB1 receptor) and Cannabined receptor 2
(cannabinoid receptor 2, CB2).Nineteen ninety, the successful clone in rat cerebral cortex cDNA library such as Matsuda
Go out CB1 receptors (Matsuda, L.A.et.al, Nature, 1990,346,561)；CB2 receptors were then existed in 1993 by Munro etc.
Successful clone in the libraries promyelocytic leukemia protein HL60CDNA of the mankind (Munro, S.et.al, Nature, 1993,
365,61).CB1 receptors and CB2 receptors belong to g protein coupled receptor (G-protein coupled receptor, GPCR)
Rhodopsin sample family, have typical 7 sections of a- spirals transmembrane structure, two kinds of complete amino acid sequences of receptor have 44% it is same
Source property, the amino acid sequence of both relatively conservative transmembrane regions have 68% homology (Pacher, P.et.al,
Pharmacol.Rev,2006,58,389).Wherein, CB2 is mainly in the cell of immune system, such as macrophage and T- cells and
Gastronintestinal system periphery is expressed, CB2 receptors also it is widely distributed in brain, wherein it is principally found in microglia and non-neuron
On.
The relevant compound of CB2 receptor stimulating agents shows preferable activity in many diseases, these disease packets
Include pain (Beltramo, M.Mini Rev Med Chem, 2009,9,11), inflammation (Cabral, G.A.et.al, J Leukoc
Biol, 2005,78,1192), colitis (Lin Sisi etc., Chinese Journal of Pathophysiology, 2015,10,195), glaucoma
(Hampson, A.J.et.al, PNAS, 1998,95,8268), liver fibrosis (Julien,
B.et.al.Gastroenterology, 2005,128,742), cerebral ischemia re-pouring injured (Lopez, R.A,
CerebCortex,2011,21,2046；Sun Jing etc., China Medicine University's journal, 2013,44,167), tumour (Deng Yuanfei, extensively
Eastern medicine, 2016,8,1109), cardiomyopathy (literary magnitude recklessly, heart journal, 2014,3,265) etc..
The diversified clinical value of CB2 receptor stimulating agents shows its bright prospects in field of medicaments, however
Up to the present, there is no CB2 receptor stimulating agents become marketed drug, thus, it is found that novel high-activity, it is highly selective and with compared with
The CB2 receptor stimulating agents of good druggability have very important significance for the field.
Summary of the invention
The present invention describes compound of formula I and/or their officinal salt
Wherein, R1For aryl, heteroaryl, R2For H, (C1-C6) linear or branched alkyl group.
Preferably, R1Selected from 2- Trifluoromethoxyphen-ls, 4- Trifluoromethoxyphen-ls, bis- Trifluoromethoxyphen-ls of 2,4-,
2- methoxyphenyls, 4- methoxyphenyls, 2,4- Dimethoxyphenyls, 2- aminomethyl phenyls, 4- aminomethyl phenyls, 2,4- dimethyl benzenes
Base, 2- fluorophenyls, 4- fluorophenyls, 2,4 difluorobenzene base, 2- chlorphenyls, 4- chlorphenyls, 2,4 dichloro benzene base, 2- pyridyl groups；Together
When R2Selected from H, methyl.I.e. for R1For substituent group, representational example is as follows,
Asterisk (*) indicates that the carbon atom of the key and piperidine ring 4 is connected.
The invention further relates to compound of formula I and/or its officinal salt for preventing and/or treating pain, inflammation, inflammatory bowel
Disease, glaucoma, diabetes, diabetic retinopathy, atherosclerosis, age-related macular degeneration, acute hepatic failure,
Liver fibrosis, pulmonary fibrosis, kidney fibrosis, systemic fibrosing, ischemia reperfusion injury, acute allograft rejection,
Chronic allograft nephrosis, diabetic nephropathy, glomerulus nephrosis, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction,
Systemic sclerosis, thermal damage, burn, hypertrophic scar, oulitis fever, hepatic sclerosis or tumour, osteoporosis, neurodegeneration, soldier
In.
The invention further relates to pharmaceutical preparation (or pharmaceutical composition), containing a effective amount of at least one compound of formula I and/
Or the excipient and carrier of its officinal salt, physiology tolerance, and also have other additives and/or other activity in due course
Ingredient.Drug can be administered orally, such as with pill, tablet, spraying piece, coating tablet, granule, hard and Perle, molten
Liquid, syrup, emulsion, suspension or aerosol mixtures form.But using may be carried out as follows：Per rectum is administered, such as with
Suppository form；Or parenteral, such as through it is intravenous, intramuscular or subcutaneously with inject solution or infusion solution, micro-capsule, implant
Or the form of implantation stick；Or percutaneous or local administration, such as with ointment, solution or tincture form；Or be administered with other approach,
Such as with aerosol or form of nasal sprays.
The pharmaceutical preparation of the present invention is prepared in a manner of known per se and be known to those skilled in the art, in addition to formula
Outside Compound I and/or their officinal salt and/or their prodrug, pharmaceutical inert inorganic and/or organic carrier are used
Substance and/or additive.For the preparation of pill, tablet, coating tablet and hard gelatin capsule, may use such as lactose,
Cornstarch or derivatives thereof, talcum, stearic acid or its salt etc..The carrier mass of Perle and suppository have for example fat,
Wax, semisolid and liquid polyol, natural or fixed oil etc..It is suitable for preparing solution, for example injects solution or emulsion or syrup
The carrier mass of agent has such as water, brine, alcohol, glycerine, polyalcohol, sucrose, inverted sugar, glucose, vegetable oil.It is suitable for
Micro-capsule, implant or be implanted into stick carrier mass, such as oxyacetic acid and lactic acid copolymer.Pharmaceutical preparation usually contains about 0.5
To the compound of formula I of about 90% weight and/or their officinal salt and/or their prodrug.In pharmaceutical preparation activity at
Compounds of formula I and/or the amount of their officinal salt and/or their prodrug normally about 0.5 to about 1000mg, preferably from about 1
To about 500mg.
Other than the active constituent of Formulas I and/or their officinal salt and carrier mass, pharmaceutical preparation can contain one kind
Or multiple additives, such as filler, disintegrant, adhesive, lubricant, wetting agent, stabilizer, emulsifier, preservative, sweet taste
Agent, colorant, corrigent, aromatic, thickener, diluent, buffer substance, solvent, solubilizer, the examination for obtaining depot effect
Agent, salt, coating agent or the antioxidant for changing osmotic pressure.They can also contain two or more compound of formula I and/or they
Officinal salt.It, can be according to medicine to the selection of individual compound when pharmaceutical composition contains two or more compound of formula I
The specific overall pharmacological property of object preparation.For example, the shorter height potent compound of acting duration can with effect compared with
Low long-acting compound combination.Permitted flexibility makes it possible to compound for substituent group selection in compound of formula I
Biology and physicochemical properties carry out numerous controls, thus, it is possible to select it is this kind of needed for compound.In addition, in addition at least one
Outside kind compound of formula I and/or its officinal salt, pharmaceutical preparation can also contain one or more other therapeutic or preventative work
Property ingredient.
When using compound of formula I, dosage can change, agent in grace period and according to conventional with known to doctor
Amount should be suitable for the individual instances of each example.It depends on particular compound, the property of treated disease for example applied
With severity, method of application and scheme or whether that is treated be acute or chronic disease or prevented.Suitable agent
Amount can utilize clinical method known to medical domain to establish.In general, result needed for being obtained in the adult for weighing about 75kg
Daily dose is about 0.01 to about 100mg/kg, preferably from about 0.1 to about 50mg/kg, especially about 0.1 to about 10mg/kg (in each feelings
With mg/kg batheroom scales under condition).Especially in the case of application relatively large amount, if daily dose can be divided into stem portion, such as 2,3
Or 4 part application.In general, according to individual behavior, it may be necessary to deviate the daily dose upward or downward.
In addition, compound of formula I can be used as preparing among other compounds, the especially synthesis of other drugs active constituent
Body can for example be obtained by introducing substituent group or modification functional group by compound of formula I.
In most cases, the reaction mixture of the final compound containing Formulas I or intermediate is post-processed, such as
It is necessary to purify product by conventional method well known by persons skilled in the art to fruit.For example, synthesized compound is available
Well known method such as crystallization, chromatography or reversed-phased high performace liquid chromatographic (RP-HPLC) or based on such as compound size, charge or
Other hydrophobic separation methods are purified.Similarly, well known method such as NMR, IR and mass spectrography (MS) can be used for characterizing
The compounds of this invention.
Therefore, following embodiment is the part of the present invention, is not intended to limit the present invention for illustrating.
It should be intended that, the active modification of the various embodiments of the non-substantial effect present invention is included in disclosed herein
The scope of the invention in.
Embodiment：
The first step：The preparation of 4- [2- (trifluoromethoxy) phenyl] piperidines -1- nitriles
By 4- [2- (trifluoromethoxy) phenyl] piperidines (10.0g, 40.8mmol), potassium carbonate (11.1g, 80.2mmol) adds
In 100mL methylene chloride/waters (1:1) in, stirring is cooled to 0 DEG C.By be dissolved in 20mL dichloromethane cyano bromine (5.3g,
It 50.0mmol) is slowly dropped into above-mentioned solution, reacts 30min at 0 DEG C, restore to room temperature the reaction was continued 2h, detach organic layer, use
Saturated sodium bicarbonate solution, saturated nacl aqueous solution wash organic layer, and organic phase is concentrated under reduced pressure in anhydrous magnesium sulfate drying, thick to produce
Product silica gel column chromatography (petrol ether/ethyl acetate=7/3) obtains 4- [2- (trifluoromethoxy) phenyl] piperidines -1- nitriles 8.9g and (receives
Rate：81%).
1H-NMR(400MHz,CDCl3):δ 7.12-7.03 (m, 2H), 6.69-6.51 (m, 2H), 3.52 (d, J=
12.0Hz,2H),3.17-3.04(m,2H),2.70-2.68(m,1H),1.98-1.83(m,2H),1.70-1.61(m,2H)；
LC/MS(M+1)+=271.1.
Second step：(E) preparation of-N- hydroxyls -4- [2- (trifluoromethoxy) phenyl] piperidines -1- carbonamidines
4- [2- (trifluoromethoxy) phenyl] piperidines -1- nitriles (8.0g, 30.0mmol) are dissolved in isopropanol/water (4/1)
In 30mL, hydroxylamine hydrochloride (10.4g, 150.0mmol) is added at room temperature, stirs 5h at 90 DEG C, is cooled to room temperature, adds into solution
Enter 6N HCl/water solution, ether washing, with aqueous sodium carbonate by water phase tune pH value to alkalescent, ether extraction is collected organic
Phase, it is dry, (E)-N- hydroxyls -4- [2- (trifluoromethoxy) phenyl] piperidines -1- carbonamidine 7.9g (yields are concentrated under reduced pressure：
87%).LC/MS(M+1)+=304.1.
Third walks：Ethyl -3- [3- [4- [2- (trifluoromethoxy) phenyl] piperidin-1-yl] -1,2,4- oxadiazole -5- bases]
The preparation of propionic ester
Into the anhydrous n,N-Dimethylformamide of 50mL containing carbonyl dimidazoles (4.5g, 27.6mmol), it is slowly added dropwise
The anhydrous n,N-Dimethylformamide solution of 30mL containing 3- (ethoxy carbonyl) propionic acid (4.4g, 30mmol), is stirred at room temperature
1h, be slowly added into solution (E)-N- hydroxyls -4- [2- (trifluoromethoxy) phenyl] piperidines -1- carbonamidines (7.0g,
23.0mmol), 5h is stirred in reaction at 110 DEG C, and after cooling, vacuum distillation removes solvent.Residue silica gel column chromatography (oil
Ether/ethyl acetate=1/1) obtain ethyl -3- [3- [4- [2- (trifluoromethoxy) phenyl] piperidin-1-yl] -1,2,4- oxadiazoles -
5- yls] propionic ester 6.8g (yields：71%).
1H-NMR(400MHz,CDCl3):δ 7.14-7.05 (m, 2H), 6.63-6.51 (m, 2H), 4.13 (q, J=7.2Hz,
2H), 3.51 (d, J=12.0Hz, 2H), 3.17 (t, J=7.6Hz, 2H), 3.12-3.04 (m, 2H), 2.72-2.70 (m, 1H),
2.61 (t, J=7.6Hz, 2H), 1.98-1.64 (m, 4H), 1.25 (t, J=7.2Hz, 3H)；LC/MS(M+1)+=414.2.
4th step：3- [3- [4- [2- (trifluoromethoxy) phenyl] piperidin-1-yl] -1,2,4- oxadiazole -5- bases] propionic acid
Preparation
By ethyl -3- [3- [4- [2- (trifluoromethoxy) phenyl] piperidin-1-yl] -1,2,4- oxadiazole -5- bases] propionic acid
60mL ethanol/waters (1 are added in ester (6.5g, 15.7mmol)：1) in, sodium hydroxide (1.9g, 47.1mmol) is added into solution,
12h is stirred at room temperature, ethyl alcohol is removed under reduced pressure, solution ph is adjusted to 5.0 with 1N HCl, ethyl acetate extraction detaches organic
Phase, aqueous salt solu-tion, dry organic phase are concentrated under reduced pressure to give 3- [3- [4- [2- (trifluoromethoxy) phenyl] piperidines -1-
Base] -1,2,4- oxadiazole -5- bases] propionic acid 5.6g (yields：93%).LC/MS(M)+=385.1.
5th step：N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- [2- (trifluoromethoxy) phenyl] piperazines
Pyridine -1- bases] -1,2,4- oxadiazole -5- bases] propionamide preparation
By 3- [3- [4- [2- (trifluoromethoxy) phenyl] piperidin-1-yl] -1,2,4- oxadiazole -5- bases] propionic acid (5.2g,
It 13.5mmol) is added in 60mL dichloromethane, 1- ethyls-(3- dimethylaminopropyls) phosphinylidyne diimine is added into solution
Hydrochloride (EDCI, 2.9g, 15.0mmol), I-hydroxybenzotriazole (HOBt, 2.0g, 15.0mmol), triethylamine (3.5g,
34.0mmol), 30min is stirred at room temperature, into reaction solution be added N- methylimidazoles [1,2-a] piperazine -6- amine (2.2g,
15.0mmol), reaction is stirred at room temperature overnight, and stops reaction, and dichloromethane mutually uses water, saturated common salt water washing, collection to have
Crude product, crude product silica gel column chromatography (petrol ether/ethyl acetate=1/ is concentrated under reduced pressure to obtain in machine phase, anhydrous sodium sulfate drying, filtering
1) N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- [2- (trifluoromethoxy) phenyl] piperidin-1-yl] -1,
2,4- oxadiazole -5- bases] propionamide 5.6g (yields：81%).
1H-NMR(400MHz,CDCl3):δ8.62(s,1H),8.31(s,1H),7.26-7.05(m,4H),6.63-6.50
(m, 2H), 3.51 (d, J=12.0Hz, 2H), 3.17 (t, J=7.6Hz, 2H), 3.12-3.04 (m, 2H), 2.72-2.70 (m,
1H), 2.71 (s, 3H), 2.61 (t, J=7.6Hz, 2H), 1.98-1.85 (m, 2H), 1.80-1.76 (m, 2H)；LC/MS(M+1
)+=516.2.
The compound of formula I for meeting claims may be used and be obtained with the approximate synthetic method of above-described embodiment, only
Different starting materials need to be changed.Representational compound is as follows：
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- [2- (trifluoromethoxy) phenyl] piperidines -1-
Base] -1,2,4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- [4- (trifluoromethoxy) phenyl] piperidines -1-
Base] -1,2,4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- [2,4- bis- (trifluoromethoxy) phenyl] piperidines -
1- yls] -1,2,4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- [2- (methoxyl group) phenyl] piperidin-1-yl] -1,
2,4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- [4- (methoxyl group) phenyl] piperidin-1-yl] -1,
2,4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- [2,4- bis- (methoxyl group) phenyl] piperidines -1-
Base] -1,2,4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (2- aminomethyl phenyls) piperidin-1-yl] -1,2,4-
Oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (4- aminomethyl phenyls) piperidin-1-yl] -1,2,4-
Oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (2,4- 3,5-dimethylphenyls) piperidin-1-yl] -1,
2,4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (2- chlorphenyls) piperidin-1-yl] -1,2,4- Evil
Diazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (4- chlorphenyls) piperidin-1-yl] -1,2,4- Evil
Diazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (2,4 dichloro benzene base) piperidin-1-yl] -1,2,
4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (2- fluorophenyls) piperidin-1-yl] -1,2,4- Evil
Diazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (4- fluorophenyls) piperidin-1-yl] -1,2,4- Evil
Diazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine]-N- methyl -3- [3- [4- (2,4 difluorobenzene base) piperidin-1-yl] -1,2,
4- oxadiazole -5- bases] propionamide；
N- [- 6 base of imidazoles (1,2-a) piperazine] -3- [3- [4- (2- pyridyl groups) piperidin-1-yl] -1,2,4- oxadiazoles -5-
Base] propionamide.
Determination of activity
Following tests is carried out to determine the activity of formula (I) compound.
Radioligand binding assay
The compounds of this invention uses the compatibility of cannabinoid CB 1 receptor expression people's CNR1 or CNR2 receptor of suggestion amount
The membrane product (PerkinElmer) of human embryo kidney (HEK) cell respectively combine 1.5 or 2.6nM [3H]-CP-55,940
(Perkin Elmer) is determined as radioligand.Be incorporated in total volume be 0.2ml combination buffer (for CB1 receptors：
50mM Tris, 5mMMgCl2,2.5mM EDTA and 0.5% (wt/vol) no fatty acids BSA, PH7.4, and for CB2 receptors：
50mM Tris, 5mMMgCl2,2.5mM EGTA and 0.1% (wt/vol) no fatty acids BSA, pH 7.4) in carry out, at 30 DEG C
Shake 1h.Pass through coated microfiltration plate (the UniFilter GF/B filter plates for having 0.5% polyethyleneimine；Packard) fast
Speed is filtered reaction terminating.For Ki using nonlinear regression analysis (Activity Base, ID Business Solution,
Limited the radioactivity of combination) is analyzed, for [3H] CP55,940 Kd values are determined from saturation testing.Formula (I) compound is aobvious
Show that the excellent compatibility for CB2 receptors, compatibility are less than 20 μM.
It is especially 1nM to 10 μM according to activity (Ki) of the compound of Formulas I in said determination, more particularly 1nM to 2 μ
M。
CAMP is measured
The Chinese hamster ovary celI for expressing people's CB1 or CB2 receptor is seeded in for 17-24 hours with 50.000 cells/wells before the experiments
In 96 hole plate of black (Corning Costar#3904) with clear flat bottom, at DMEM (Invitrogen No.31331)
In, 1x HT are supplemented, there is 10% fetal calf serum, and incubated 30 minutes at 5%CO2 and 37 DEG C in the incubator of moistening.Add
It is 100 μ l to enter compound to the final volume that measures, and is incubated 30 minutes at 30 DEG C.Use cAMP-Nano-TRF detection reagents
Box (Roche Diagnostics), by be added 50 μ l lytic reagents (Tris, NaCl, 1.5%Triton X100,2.5%
NP40,10%NaN3) and 50 μ l detection solution (20 μM of mAbAlexa700-cAMP 1：1 and 48 μM of ruthenium -2-AHA-cAMP) eventually
It only measures, and shaken at room temperature 2h.By being equipped with ND：TRF reader (Evotec of the YAG laser as lasing light emitter
Technologies GmbH) time of measuring resolution energy transfer.Twice by plane-table operation, in 355nm excitations and respectively 730
(bandwidth 30nm) or 645nm (bandwidth 75nm) are with door (gate) transmitting of the delay of 100ns and 100ns, total exposure duration
10s.FRET signals calculate as follows：FRET=T730-Alexa730-P (T645-B645), P=Ru730-B730/Ru645-
B645, wherein T730 are the instrument connections measured in 730nM, and T645 is the instrument connection measured in 645nM, and B730 and B645 are difference
In the buffer control of 730nM and 645nM.CAMP contents are from span for from 10 μM to the function of the standard curve of 0.1nMcAMP
To measure.
EC50 values are measured using Activity Base analyses (ID Business Solution, Limited).From the survey
The EC50 values of the cannabinoid agonists of the wide scope of fixed output quota life are coincide with value disclosed in scientific literature.
All compounds according to the present invention are CB2 agonists, and EC50 is less than 5uM, particularly lower than 2uM.For example,
Following compound is shown in above-mentioned function cAMP measurement with lower people EC50 values (being expressed with uM)：
Claims (4)
1. compound of formula I and/or their officinal salt
Wherein, R1Selected from 2- Trifluoromethoxyphen-ls, 4- Trifluoromethoxyphen-ls, bis- Trifluoromethoxyphen-ls of 2,4-, 2- methoxyl groups
Phenyl, 4- methoxyphenyls, 2,4- Dimethoxyphenyls, 2,4- 3,5-dimethylphenyls, 2- fluorophenyls, 4- fluorophenyls, 2,4- difluoros
Phenyl, 2- chlorphenyls, 4- chlorphenyls, 2,4 dichloro benzene base, 2- pyridyl groups；R simultaneously2Selected from H, methyl.
2. at least one type I compound and/or its officinal salt described in claim 1 are in the case where preparing prevention and/or treatment
Purposes in the drug of row disease：Pain, inflammation, inflammatory bowel disease, glaucoma, diabetes, diabetic retinopathy, artery
Atherosis, age-related macular degeneration, acute hepatic failure, liver fibrosis, pulmonary fibrosis, kidney fibrosis, it is systemic fibrosing,
Ischemia reperfusion injury, acute allograft rejection, chronic allograft nephrosis, diabetic nephropathy, glomerulonephritis
Disease, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal damage, burn, hypertrophic scar, oulitis fever, liver are hard
Change or tumour, osteoporosis, neurodegeneration, palsy.
3. the purposes described in claim 2, disease therein refers to that inflammation, inflammatory bowel disease, glaucoma, diabetes, kidney are fine
Dimensionization, myocardial ischemia, myocardial infarction.
4. drug, it includes described in a effective amount of claim 1 at least one compound of formula I and/or its officinal salt, life
The excipient and carrier of Neo-Confucianism tolerance, and also have other additives and/or other active components in due course.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610689120.6A CN106317059B (en) | 2016-08-19 | 2016-08-19 | A kind of 2 (CB2) agonist of Cannabined receptor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610689120.6A CN106317059B (en) | 2016-08-19 | 2016-08-19 | A kind of 2 (CB2) agonist of Cannabined receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106317059A CN106317059A (en) | 2017-01-11 |
| CN106317059B true CN106317059B (en) | 2018-10-12 |
Family
ID=57743245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610689120.6A Active CN106317059B (en) | 2016-08-19 | 2016-08-19 | A kind of 2 (CB2) agonist of Cannabined receptor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106317059B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019025474A1 (en) * | 2017-08-02 | 2019-02-07 | Centro Cardiologico Monzino S.p.A. | Modulation of endocannabinoid system and uses thereof in the context of induced pluripotent stem cell-based applications and therapy for cardiomyopathies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007096764A2 (en) * | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
| WO2008141239A1 (en) * | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors |
| PT2963037T (en) * | 2013-02-27 | 2019-04-23 | Mochida Pharm Co Ltd | Novel pyrazole derivative |
-
2016
- 2016-08-19 CN CN201610689120.6A patent/CN106317059B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106317059A (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60038185T2 (en) | ARLY AND HETEROARYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS INHIBITORS OF THE RECOVERY OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE | |
| CN104093716B (en) | Biaryl ether sulfonamide compounds and its purposes as therapeutic agent | |
| CN105308033B (en) | JAK2 and ALK2 inhibitor and its application method | |
| EP2049518B1 (en) | Indazole and isoindole derivatives as glucokinase activating agents. | |
| CN102731492B (en) | Cyclohexanes derivant, its preparation method and in application pharmaceutically | |
| CN113493447A (en) | GLP-1 receptor agonists | |
| DE69912279T2 (en) | 5-HT1F AGONISTS | |
| CN101277952B (en) | Isoxazole derivatives | |
| CN113816948A (en) | Condensed imidazole derivative, preparation method and application thereof in medicine | |
| CN101090895A (en) | Aryl sulphonamide modulators | |
| JP2005507423A (en) | Heteroarylamines as glycogen synthase kinase 3 beta inhibitors (GSK3 inhibitors) | |
| EP3331532B1 (en) | Substituted aminoquinazoline compounds as a2a antagonist | |
| TW201127831A (en) | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | |
| JP2002510695A (en) | Thiazolo [4,5-d] pyrimidines and pyridines as corticotropin releasing factor (CRF) antagonists | |
| WO2016148232A1 (en) | Morphinan derivative | |
| JP2020530451A (en) | Antagonist of muscarinic acetylcholine receptor M4 | |
| DE69922594T2 (en) | Indazole derivatives as 5-HT1F agonists | |
| KR20010114273A (en) | Di-substituted iminoheterocyclic compounds | |
| CN107530349B (en) | Xanthine substituted alkynyl carbamates/trans carbamates as A2B antagonists | |
| EP1572698B1 (en) | 3-substituted 3,4-dihydro-thieno¬2,3-d pyrimidine-4-one-derivatives, production and use thereof | |
| DE4107521A1 (en) | NEW ACYLAMINOSUBSTITUTED HETRAZEPINE | |
| CN106317059B (en) | A kind of 2 (CB2) agonist of Cannabined receptor | |
| CN106317043B (en) | A kind of 2 agonist of Cannabined receptor | |
| CN102372701A (en) | Azabicyclo hexane derivative, preparation method, and application of azabicyclo hexane derivative in medicine | |
| CN104418820A (en) | Carboxylic acid derivative as lysophosphatidic acid receptor antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |